Build the infrastructure that finds what fragmented care misses.
MbeleMed exists to make serious cardiac risk easier to identify, route through qualified review, and convert into accountable action, especially for populations traditional pathways reach late.
Philip Butler
Philip is a healthcare investor and operator with experience across value-based care, cardiac monitoring, company building, and strategic finance.
MbeleMed’s origin is personal. A family member’s undiagnosed atrial fibrillation made the cost of late detection real before the company existed.
The cost of late detection was personal before it was professional.
Maturity should be visible, not implied.
Clinicians retain authority
No autonomous diagnosis, treatment, prescribing, or replacement of qualified clinical judgment.
Claims carry maturity
Published evidence, modeled economics, demonstrated workflow, pilot-stage work, and roadmap remain distinct.
Economics stay transparent
MbeleMed’s fee, device cost, professional interpretation, downstream care, and partner economics are not blended into one universal claim.
Reach the overlooked
Deployment should move closer to high-risk populations without weakening clinical governance.
Device-agnostic by design
The operating layer should work across appropriate monitoring partners rather than depend on implied device ownership.
Earn expansion
Start with a defined pilot, measure the workflow honestly, and expand only when the evidence supports it.
High-risk senior populations and accountable healthcare organizations.
MbeleMed’s primary commercial wedge centers on health plans, value-based care organizations, health systems, physician groups, and access partners responsible for finding and acting on silent cardiac risk.
Emerging applications, including maternal cardiac instability, remain separately labeled as research or pilot-stage work.
Build a credible pathway.
Tell us what population, clinical process, and evidence your organization is responsible for.